NeOnc Technologies Advances Brain Cancer Therapy NEO-212 to FDA Phase 2 Trial

Sep 10, 2025

Biotech investors and healthcare innovators: NeOnc Technologies Holdings has received FDA authorization to advance its NEO-21201 brain cancer therapy into Phase 2 clinical trials.

📌 Key Highlights:

Phase 1 trial showed safe dosing up to 810mg daily (5 of 28 days)

Phase 2 trial authorization granted by the FDA

Enrollment expected to start before end of 2025

Targeting glioblastoma, astrocytoma, and other aggressive CNS cancers

Potential to replace TMZ as future standard of care

NEO-212 represents a transformative step forward in brain cancer treatment.

🔖 YouTube Tags:

#NeOncTechnologies #NTHI #NEO212 #BrainCancerResearch #Glioblastoma #Astrocytoma #CNSCancer #FDAApproval #Phase2Trial #BiotechInvesting #CancerTherapy #HealthcareInnovation #ClinicalTrials #NewsOut #JaneKing